ERBB2 and breast carcinoma: For early HER2+ breast cancer patients, Tzm prevents up to 40% of recurrence during the 10 years after surgery [6], and for metastatic HER2+ breast cancer patients, first-line use of Tzm concurrently with chemotherapy significantly prolongs progression-free survival by 3 months [7].